A detailed history of Wells Fargo & Company transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Wells Fargo & Company holds 260,415 shares of NBIX stock, worth $30.6 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
260,415
Previous 234,969 10.83%
Holding current value
$30.6 Million
Previous $32.3 Million 7.32%
% of portfolio
0.01%
Previous 0.01%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$114.58 - $153.15 $2.92 Million - $3.9 Million
25,446 Added 10.83%
260,415 $30 Million
Q2 2024

Aug 13, 2024

BUY
$130.86 - $143.19 $1.72 Million - $1.88 Million
13,155 Added 5.93%
234,969 $32.3 Million
Q1 2024

May 10, 2024

BUY
$130.4 - $143.74 $15.5 Million - $17.1 Million
118,786 Added 115.29%
221,814 $30.6 Million
Q4 2023

Feb 09, 2024

SELL
$106.07 - $132.76 $476,572 - $596,490
-4,493 Reduced 4.18%
103,028 $13.6 Million
Q3 2023

Nov 13, 2023

BUY
$94.02 - $117.1 $446,406 - $555,990
4,748 Added 4.62%
107,521 $12.1 Million
Q2 2023

Aug 15, 2023

BUY
$89.53 - $104.87 $1.03 Million - $1.21 Million
11,559 Added 12.67%
102,773 $9.69 Million
Q1 2023

May 12, 2023

BUY
$94.11 - $123.02 $91,192 - $119,206
969 Added 1.07%
91,214 $9.23 Million
Q4 2022

Feb 13, 2023

BUY
$106.72 - $127.06 $266,800 - $317,650
2,500 Added 2.85%
90,245 $10.8 Million
Q3 2022

Nov 14, 2022

SELL
$92.03 - $107.81 $214,798 - $251,628
-2,334 Reduced 2.59%
87,745 $9.32 Million
Q2 2022

Aug 12, 2022

SELL
$75.79 - $100.07 $1.04 Million - $1.37 Million
-13,684 Reduced 13.19%
90,079 $8.78 Million
Q1 2022

May 16, 2022

BUY
$72.45 - $94.81 $832,812 - $1.09 Million
11,495 Added 12.46%
103,763 $9.73 Million
Q4 2021

Feb 14, 2022

SELL
$79.65 - $106.22 $15.9 Million - $21.2 Million
-199,713 Reduced 68.4%
92,268 $7.86 Million
Q3 2021

Nov 15, 2021

SELL
$86.18 - $99.03 $7.11 Million - $8.17 Million
-82,475 Reduced 22.03%
291,981 $28 Million
Q2 2021

Aug 16, 2021

BUY
$89.43 - $102.27 $6.32 Million - $7.22 Million
70,615 Added 23.24%
374,456 $36.4 Million
Q1 2021

May 13, 2021

SELL
$87.57 - $119.4 $1.87 Million - $2.56 Million
-21,408 Reduced 6.58%
303,841 $29.5 Million
Q4 2020

Feb 09, 2021

BUY
$86.91 - $108.33 $1.9 Million - $2.37 Million
21,837 Added 7.2%
325,249 $31.2 Million
Q3 2020

Nov 05, 2020

BUY
$96.16 - $135.15 $2.15 Million - $3.03 Million
22,387 Added 7.97%
303,412 $29.2 Million
Q2 2020

Aug 13, 2020

BUY
$85.09 - $130.36 $3.3 Million - $5.05 Million
38,758 Added 16.0%
281,025 $34.3 Million
Q1 2020

May 14, 2020

BUY
$75.11 - $113.76 $18.2 Million - $27.6 Million
242,267 New
242,267 $21 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $11.2B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.